Suppr超能文献

在常规日常实践中,羧甲麦芽糖铁治疗炎症性肠病患者缺铁性贫血的安全性和疗效。

Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.

机构信息

Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany.

Department of Gastroenterology and Clinical Nutrition, DGD Clinics Sachsenhausen, Frankfurt/Main, Germany.

出版信息

J Crohns Colitis. 2018 Jun 28;12(7):826-834. doi: 10.1093/ecco-jcc/jjy042.

Abstract

INTRODUCTION

Iron deficiency and iron deficiency anaemia are common complications in inflammatory bowel disease [IBD] patients. Anaemia in IBD is attributable to chronic blood loss and/or impaired iron intake and absorption. International guidelines recommend intravenous iron supplementation in IBD patients, since oral supplements are frequently poorly tolerated and can exacerbate inflammation. Intravenous ferric carboxymaltose [FCM; Ferinject® 50 mg ferric iron[III]/mL suspension] was approved in Europe in 2007 for correction of iron deficiency, and can be administered in single 15-min infusions of up to 1000 mg.

METHODS

A prospective non-interventional post-marketing study was performed in 101 centres in Germany to assess the efficacy, tolerability, and convenience of Ferinject® in clinical practice in a large cohort of IBD patients. Primary endpoints were haemoglobin [Hb] normalisation or increase ≥2 g/dL [responders], and normalisation of serum ferritin [s-ferritin] and transferrin saturation. Adverse events [AEs], clinical signs/symptoms, and disease activity indices were also analysed.

RESULTS

In all, 224 subjects (127 Crohn's disease [CD]; 97 ulcerative colitis [UC]) were treated. Mean total iron dose was 1139 mg [range: 100 mg-4800 mg], with 76.7% of doses between 500 mg and 2000 mg; 63.3% of patients responded, and no adverse drug reactions or drug-attributed serious adverse events [SAEs] or deaths occurred. Mean increases of Hb [10.0 to 12.3 g/dL], ferritin [52 μg/L to 103 μg/L], transferrin saturation [TSAT, 15% to 25%], and s-iron [6.1 to 12.4 μmol/L] were significant [p = 0.0001]. Clinical scores and quality of life improved due to the amelioration of anaemia symptoms.

CONCLUSIONS

Ferinject®-therapy was proven to be effective and safe in a large cohort of patients with IBD-associated anaemia in routine practice. Rapid, high-dose application is convenient for physicians and reduces patients' time lost from work.

摘要

简介

缺铁和缺铁性贫血是炎症性肠病(IBD)患者常见的并发症。IBD 中的贫血归因于慢性失血和/或铁摄入和吸收受损。国际指南建议 IBD 患者使用静脉铁补充剂,因为口服补充剂通常耐受性差,并可能加重炎症。静脉注射羧麦芽糖铁[FCM;Ferinject®50mg 三价铁[III]/mL 混悬液]于 2007 年在欧洲获批用于纠正缺铁,可以单次 15 分钟输注高达 1000mg。

方法

在德国的 101 个中心进行了一项前瞻性非干预性上市后研究,以评估 Ferinject®在 IBD 患者大队列中的临床实践中的疗效、耐受性和便利性。主要终点是血红蛋白[Hb]正常化或增加≥2g/dL[应答者],以及血清铁蛋白[s-铁蛋白]和转铁蛋白饱和度正常化。还分析了不良事件[AE]、临床体征/症状和疾病活动指数。

结果

共有 224 名受试者(127 名克罗恩病[CD];97 名溃疡性结肠炎[UC])接受了治疗。总铁剂量平均为 1139mg[范围:100mg-4800mg],500mg-2000mg 之间的剂量占 76.7%;63.3%的患者有反应,没有药物不良反应或药物相关的严重不良事件[SAE]或死亡。Hb[10.0 至 12.3g/dL]、铁蛋白[52μg/L 至 103μg/L]、转铁蛋白饱和度[TSAT,15%至 25%]和 s-铁[6.1 至 12.4μmol/L]的平均增加均具有统计学意义[p=0.0001]。由于贫血症状的改善,临床评分和生活质量得到改善。

结论

Ferinject®治疗在常规实践中在患有 IBD 相关贫血的大型患者队列中被证明是有效和安全的。快速、高剂量的应用对医生来说很方便,并减少了患者因工作而失去的时间。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验